Author:
Thomson A H,Vasey P A,Murray L S,Cassidy J,Fraier D,Frigerio E,Twelves C
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Amantea, MA, Forrest, A, Northfelt, DW & Mamelok, R (1997). Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi’s sarcoma. Clin Pharmacol Ther 61: 301–311.
2. Beal, SL, Sheiner, LB & Boeckmann, AJ (1994). NONMEM IV User’s Guide, Parts I–VI, NONMEM Project Group, University of California, San Francisco
3. Bronchud, MH, Margison, JM, Howell, A, Lind, M, Lucas, SB & Wilkinson, PM (1990). Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. Cancer Chemother Pharmacol 25: 435–439.
4. Bruno, R, Vivier, N, Vergniol, JC, DePhillips, SL, Montay, G & Sheiner, LB (1996). A population pharmacokinetic model for taxotere: model building and validation. J Pharmacokinet Biopharm 24: 153–172.
5. Chabot, GG, Abigerges, D, Catimel, G, Culine, S, Deforni, R, Extra, JM, Mahjoubi, H, Herait, P, Armand, JP, Bugat, R, Clavel, M & Marty, ME (1995). Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during Phase I trials. Ann Oncol 6: 141–151.
Cited by
81 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献